Caris Life Sciences (CAI) Common Equity (2024 - 2026)

Caris Life Sciences' Common Equity history runs 3 years deep, the most recent figure standing at $593.5 million for Q1 2026.

• On a quarterly basis, Common Equity rose 122.83% year-over-year to $593.5 million in Q1 2026; TTM through Mar 2026 was $593.5 million, a 122.83% increase from a year earlier, with the FY2025 full-year figure at $577.3 million, up 123.1% from the prior year.
• Common Equity improved to $593.5 million in Q1 2026 per CAI's latest filing, from $577.3 million in the prior quarter.
• Across five years, Common Equity topped out at $593.5 million in Q1 2026 and bottomed at -$2.6 billion in Q1 2025.
• The 3-year median for Common Equity is -$953.3 million (2024), against an average of -$974.8 million.
• Biggest YoY gain for Common Equity was 123.1% in 2025; the steepest drop was 119.19% in 2025.
• Year by year, Common Equity stood at -$2.5 billion in 2024, then surged by 123.1% to $577.3 million in 2025, then gained by 2.8% to $593.5 million in 2026.
• Per Business Quant, the three latest CAI Common Equity figures stand at $593.5 million (Q1 2026), $577.3 million (Q4 2025), and $478.4 million (Q3 2025).